60 degrees pharmaceuticals, inc.SXTP.US Overview

US StockHealthcare

(No presentation for SXTP)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

SXTP Overall Performance

SXTP AI Analysis & Strategy

SXTP Recent Performance

3.55%

60 degrees pharmaceuticals, inc.

0.81%

Avg of Sector

-1.14%

S&P500

SXTP PowerScanner

SXTP Key Information

SXTP Valuation Metrics

SXTP Earnings Table

SXTP Profile

60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.